| Predicate |
Object |
| contentType |
Editorial|Comment |
| endingPage |
53 |
| issn |
0920-1211 |
| pageRange |
52-53 |
| publicationName |
Epilepsy Research |
| startingPage |
52 |
| bibliographicCitation |
Privitera M. Generic antiepileptic drug equivalence: The journey from anecdotes to evidence. Epilepsy Res. 2017 Aug;134():52–3. doi: 10.1016/j.eplepsyres.2017.04.005. PMID: 28595755. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_df30fd9221485622d823345d95b983e1 |
| date |
201708 |
| identifier |
https://pubmed.ncbi.nlm.nih.gov/28595755
https://doi.org/10.1016/j.eplepsyres.2017.04.005 |
| isPartOf |
https://portal.issn.org/resource/ISSN/0920-1211
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/3587 |
| language |
English |
| source |
https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/ |
| title |
Generic antiepileptic drug equivalence: The journey from anecdotes to evidence |
| discusses |
http://id.nlm.nih.gov/mesh/M0025275
http://id.nlm.nih.gov/mesh/M0001382 |
| hasPrimarySubjectTerm |
http://id.nlm.nih.gov/mesh/D013810
http://id.nlm.nih.gov/mesh/D000927 |
| hasSubjectTerm |
http://id.nlm.nih.gov/mesh/D016568
http://id.nlm.nih.gov/mesh/D006801 |